Edition:
United Kingdom

Corcept Therapeutics Inc (CORT.OQ)

CORT.OQ on NASDAQ Stock Exchange Capital Market

13.61USD
18 Jul 2018
Change (% chg)

-- (--)
Prev Close
$13.61
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
382,765
52-wk High
$25.92
52-wk Low
$11.88

Chart for

About

Corcept Therapeutics Incorporated is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The Company is developing mifepristone, a compound that modulates the effects of cortisol by acting as a competitive... (more)

Overall

Beta: 2.07
Market Cap(Mil.): $2,309.91
Shares Outstanding(Mil.): 113.40
Dividend: --
Yield (%): --

Financials

  CORT.OQ Industry Sector
P/E (TTM): 101.94 30.93 32.76
EPS (TTM): 0.20 -- --
ROI: 50.69 15.07 14.61
ROE: 52.76 16.60 16.34

BRIEF-Corcept Therapeutics Reports Qtrly Revenue $57.7 Million

* CORCEPT THERAPEUTICS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

08 May 2018

BRIEF-Corcept Therapeutics Files Lawsuit Against Teva Pharmaceuticals For Infringement Of Korlym Patents

* CORCEPT THERAPEUTICS FILES LAWSUIT AGAINST TEVA PHARMACEUTICALS FOR INFRINGEMENT OF KORLYM PATENTS

15 Mar 2018

BRIEF-Corcept Therapeutics Q4 GAAP Earnings Per Share $0.77

* CORCEPT THERAPEUTICS ANNOUNCES 2017 FINANCIAL RESULTS AND POSITIVE INTERIM RESULTS OF RELACORILANT PHASE 2 TRIAL

22 Feb 2018

BRIEF-Corcept Therapeutics Q4 GAAP Earnings Per Share $0.77

* CORCEPT THERAPEUTICS ANNOUNCES 2017 FINANCIAL RESULTS AND POSITIVE INTERIM RESULTS OF RELACORILANT PHASE 2 TRIAL

22 Feb 2018

BRIEF-Corcept Therapeutics Receives Letter on saying Teva Pharmaceuticals USA Submitted An Abbreviated New Drug Application

* CORCEPT THERAPEUTICS - RECEIVED PARAGRAPH IV NOTICE LETTER ADVISING THAT TEVA PHARMACEUTICALS USA SUBMITTED AN ABBREVIATED NEW DRUG APPLICATION TO FDA

05 Feb 2018

Competitors

Earnings vs. Estimates